Western Europe
Western Europe Pharmaceuticals & Healthcare Insight provides country-by-country analysis of the key trends impacting the prescription, OTC and generic drugs industries across Western Europe. Western Europe Pharmaceuticals & Healthcare Insight includes competitive intelligence on the growth strategies of leading national and multinational companies, along with 5-year industry forecasts for each country. The service includes access to the very latest analysis, a searchable archive of articles and data and the ability to download PDFs of current and back issues.
›› To gain FREE online access for 14 days and to download a FREE PDF, click trial.
›› To receive 15 monthly pdf issues for the price of 12 and to gain immediate online access, click subscribe.
Industry
GlaxoSmithKline (GSK) is a leading global manufacturer of prescription medicines and consumer healthcare products. The company has offices in over 100 countries and major research centres in the UK, US, Belgium and China. GSK's shares are listed on the London and New York Stock Exchanges and its corporate head office is located in the
2013-05-02Italy / Industry
BMI View: Governments across Europe are focussing on cost containment. The consequent scrutiny on drug prices and medicine consumption will subsequently put pressure on companies and...
2013-02-22Switzerland / Industry
BMI View: Novartis' U-turn over CEO Daniel Vasella's exit package could fuel support for a March 3 2013 referendum in Switzerland that proposes changes to Swiss corporate laws, including...
2013-02-20Industry Developments
GlaxoSmithKline (GSK) is a leading global manufacturer of prescription medicines and consumer healthcare products. The company has offices in over 100 countries and major research centres...
2013-05-02Italy
BMI View: Governments across Europe are focussing on cost containment. The consequent scrutiny on drug prices and medicine consumption will subsequently put pressure on companies and...
2013-02-22Switzerland
BMI View: Novartis' U-turn over CEO Daniel Vasella's exit package could fuel support for a March 3 2013 referendum in Switzerland that proposes changes to Swiss corporate laws, including...
2013-02-20Denmark
BMI View: The FDA rejection of Tresiba and Ryzodeg has led to a significant revision of earnings expectations for the market. Novo Nordisk's share price tumbled after February 12th....
2013-02-19
